Close
Close

Magic™ Antibody Discovery - Human CD19 (20-291) Membrane Protein, Partial, -mIgG2a Fc tag (CAT#: MP1209F)

Datasheet
This membrane protein is Human CD19 (20-291). It has been tested in SDS-PAGE, ELISA, BLI. We provide this protein to facilitate your membrane protein antibody discovery and development.

Product Specifications

  • Host Species
  • Human
  • Target Protein
  • CD19
  • Protein Length
  • ECD
  • Molecular Weight
  • The protein has a calculated MW of 57.0 kDa. The protein migrates as 75 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
  • Sequence
  • AA Pro 20 - Lys 291 (Accession # P15391-1).

Product Description

  • Activity
  • Yes
  • Application
  • SDS-PAGE, ELISA, BLI
  • Expression Systems
  • HEK293
  • Tag
  • Mouse IgG2a Fc tag at the C-terminus
  • Protein Format
  • Soluble
  • Reconstitution
  • Please see Certificate of Analysis for specific instructions.
  • Endotoxin
  • <0.1 EU/μg by the LAL method
  • Purity
  • >95% as determined by SDS-PAGE.
  • Buffer
  • Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Target

  • Target Protein
  • CD19
  • Full Name
  • CD19 molecule
  • Introduction
  • This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms.
  • Alternative Names
  • CD19, CD19 molecule, CD19 antigen, B-lymphocyte antigen CD19, differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte surface antigen B4, B4, CVID3, MGC12802,

Customer reviews and Q&As    

Related Products
Online Inquiry
CONTACT US
USA:
Europe:
Germany:
Call us at:
USA:
UK:
Germany:
Fax:
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us
© 2024 Creative Biolabs. | Contact Us